Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 26 March 2013
Vol. 6, Issue 268, p. rs6
[DOI: 10.1126/scisignal.2003573]


Editor's Summary

Therapeutic Targeting with Phosphoproteomics
Because oncogenic mutations frequently occur in genes encoding kinases, kinase inhibitors are often used as cancer therapeutics. However, because of the complexity of kinase signaling networks and the heterogeneous nature of oncogenic mutations, it is difficult to predict how cancer cells will respond to a given kinase inhibitor. Casado et al. performed phosphoproteomic analysis of human acute myeloid leukemia (AML) cell lines and used a computational approach of "signal averaging" to reduce the noise in the phosphoproteomics data, thus monitoring global kinase activation patterns as well as the effects of select inhibitors. In addition to identifying kinase networks associated with AML, this approach accurately predicted the relative sensitivities of patient-derived AML cells to inhibitors. Such profiling of kinase networks could be applied to stratify cancers based on their predicted responses to kinase inhibition.

Citation: P. Casado, J.-C. Rodriguez-Prados, S. C. Cosulich, S. Guichard, B. Vanhaesebroeck, S. Joel, P. R. Cutillas, Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells. Sci. Signal. 6, rs6 (2013).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882